The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model

Clinical Microbiology and Infection

Volumn 5, Issue 4, 1999, Pages 195-200

  MacGowan, Alasdair P ^a   Bowker, Karen E ^a   Wootton, Mandy ^a   Holt, H Alan ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Haemophilus influenzae; In vitro model; Moraxella catarrhalis; Moxifloxacin; Pharmacodynamics

Indexed keywords

MOXIFLOXACIN;

ARTICLE; BACTERICIDAL ACTIVITY; BLOOD LEVEL; CELL MUTANT; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0032942547     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00123.x     Document Type: Article

References (22)

1. Guest JF, Morris A. Community-acquired lower respiratory tract infections: the annual cost to the National Health Service. B J Med Econ 1996; 10: 263-73
2. Berk SL, Kalbfleisch JH, The Alexander Project Collaborative Group. Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in Western Europe and the USA. J Antimicrob Chemother 1996; 38(suppl A): 85-96.
3. Doern GV, The Alexander Project Collaborative Group. Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: result of a 1992-3 Western Europe and USA collaborative surveillance study. J Antimicrob Chemother 1996; 38(suppl A): 59-69.
4. Brown NM, Bedford KA, Holt HA, McCulloch SY, MacGowan AP, Reeves DS. Cefuroxime resistance in Haemophilus influenzae. Lancet 1992; 340: 552.
5. James PA, Hossain FK, Lewis DA, White DG. β-Lactam susceptibility of Haemophilus influenzae strains showing reduced susceptibility to cefuroxime. J Antimicrob Chemother 1993; 32: 239-49.
6. Gould IM, Forbes KJ, Gordon GS. Quinolone resistant Haemophilus influenzae. J Antimicrob Chemother 1994; 33: 187-8.
7. Baquero F. Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative study. J Antimicrob Chemother 1996; 38(suppl A): 117-32.
8. Wise R, Andrews JM. The activity of grepafloxacin against respiratory pathogens in the UK. J Antimicrob Chemother 1997; 40(suppl A): 27-30.
9. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 1208039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639-52.
10. Sanfilippo A, Morozowich W. An experimental model for the study of the antibacterial activity of sulphonamides. Chemotherapy 1968; 13: 54-60.
11. Li RC, Hu ZY. In vitro models for the prediction of antimicrobial activity: a pharmacokinetic and pharmacodynamic perspective. J Chemother 1997; 9(suppl): 55-65.
12. Bowker KE, Holt HA, Lewis RJ, Reeves DS, MacGowan AP. Comparative pharmacodynamics of meropenem using an in vitro model to simulate once, twice and three times daily dosing in humans. J Antimicrob Chemother 1998; 42: 461-8.
13. Dalhoff A, Petersen U, Endeimann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42: 410-25.
14. British Society for Antimicrobial Chemotherapy Working Party. A guide to sensitivity testing. J Antimicrob Chemother 1991; 27(suppl A): 22-35.
15. Broughall JM, Aminoglycosides. In: Reeves DS, Phillips I, Williams DJ & Wise R eds. Laboratory methods in antimicrobial chemotherapy. Edinburgh: Churchill Livingstone, 1998: 194-206.
16. Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, 3 novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 1997; 41: 1594-7.
17. Fass RJ. In vitro activity of BAY 12-8039, a new 8 methoxyquinolone. Antimicrob Agents Chemother 1997; 41: 1818-24.
18. Woodcock JM, AndrewsJM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101-6.
19. Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of BAY 12-8039 on Gram-positive and Gram-negative organisms as demonstrated by studies of time-kill kinetics and post antibiotic effect. Antimicrob Agents Chemother 1997; 41: 1377-9.
20. Herrington JA, Remy JM, Federici JA, Hugenel ED. The bactericidal activity of BAY 12-8039 against respiratory pathogens at clinically achievable concentrations [abstract F125]. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. Washington DC: American Society for Microbiology, 1997: 167.
21. Stass HH, Dietrich H, Sachse E. Influence of four times dosing of 500 mg probenecid on kinetics of Bay 12-8039 after administration of a single 400mg dose in healthy male volunteers [abstract F154]. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Washington DC: American Society for Microbiology, 1997: 172.
22. Sullivan JT, Woodruff M, Lettieri J, Aganval V, Krol G, Heller A. Pharmacokinetics (PK) and tolerabiliry of the new quinolone Bay 1208039: 10 days treatment at 400 mg daily [abstract P389]. Clin Microbiol Infect 1997; 3(suppl 2): 87.